You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
I. Growth failure in children due to human growth hormone deficiency,II. Growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis,III. Growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (CRI),IV. Growth disturbance (current height standard deviation score (H SDS) <-2.5 and parental adjusted H SDS <-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2 standard deviations (SD), who failed to show catch-up growth (height velocity standard deviation score (HV SDS) <0 during the last year) by four years of age or later,V. SAIZEN is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak GH concentrations of less than 2.5 nanogram/mL. Adults must also fulfil the following criteria:,Childhood onset:,Patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with SAIZEN is started,Adult onset:,Patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
I. Growth failure in children due to human growth hormone deficiency,II. Growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis,III. Growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (CRI),IV. Growth disturbance (current height standard deviation score (H SDS) <-2.5 and parental adjusted H SDS <-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2 standard deviations (SD), who failed to show catch-up growth (height velocity standard deviation score (HV SDS) <0 during the last year) by four years of age or later,V. SAIZEN is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak GH concentrations of less than 2.5 nanogram/mL. Adults must also fulfil the following criteria:,Childhood onset:,Patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with SAIZEN is started,Adult onset:,Patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.
I. Growth failure in children due to human growth hormone deficiency,II. Growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis,III. Growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (CRI),IV. Growth disturbance (current height standard deviation score (H SDS) <-2.5 and parental adjusted H SDS <-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2 standard deviations (SD), who failed to show catch-up growth (height velocity standard deviation score (HV SDS) <0 during the last year) by four years of age or later,V. SAIZEN is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak GH concentrations of less than 2.5 nanogram/mL. Adults must also fulfil the following criteria:,Childhood onset:,Patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with SAIZEN is started,Adult onset:,Patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
I. Growth failure in children due to human growth hormone deficiency,II. Growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis,III. Growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (CRI),IV. Growth disturbance (current height standard deviation score (H SDS) <-2.5 and parental adjusted H SDS <-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2 standard deviations (SD), who failed to show catch-up growth (height velocity standard deviation score (HV SDS) <0 during the last year) by four years of age or later,V. SAIZEN is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak GH concentrations of less than 2.5 nanogram/mL. Adults must also fulfil the following criteria:,Childhood onset:,Patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with SAIZEN is started,Adult onset:,Patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.
I. Growth failure in children due to human growth hormone deficiency,II. Growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis,III. Growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (CRI),IV. Growth disturbance (current height standard deviation score (H SDS) <-2.5 and parental adjusted H SDS <-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2 standard deviations (SD), who failed to show catch-up growth (height velocity standard deviation score (HV SDS) <0 during the last year) by four years of age or later,V. SAIZEN is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak GH concentrations of less than 2.5 nanogram/mL. Adults must also fulfil the following criteria:,Childhood onset:,Patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with SAIZEN is started,Adult onset:,Patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
I. Growth failure in children due to human growth hormone deficiency,II. Growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis,III. Growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (CRI),IV. Growth disturbance (current height standard deviation score (H SDS) <-2.5 and parental adjusted H SDS <-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2 standard deviations (SD), who failed to show catch-up growth (height velocity standard deviation score (HV SDS) <0 during the last year) by four years of age or later,V. SAIZEN is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak GH concentrations of less than 2.5 nanogram/mL. Adults must also fulfil the following criteria:,Childhood onset:,Patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with SAIZEN is started,Adult onset:,Patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
